BioCentury | Jul 18, 2019
Financial News

July 17 Financial Quick Takes: Chipscreen's Shanghai listing advances; plus Avrobio, Repligen and Seer

...13%) to $8.76 on Wednesday. Repligen raises $370M via sales of stock, notes Bioprocessing company Repligen Corp....
...million shares at $87 in an upsized follow-on. The price is a 1.2% premium to Repligen’s...
...CMS, joined its board. Undisclosed other investors participated in the financing. Hongjiang Li, Staff Writer AVR-RD-01, avr-02 Avrobio Inc. Repligen Corp. Seer...
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...NASDAQ:VCYT) 5/2/19 $147.1 $1,112.1 $1,363.8 23% Magenta Therapeutics Inc. (NASDAQ:MGTA) 5/1/19 $64.8 $520.6 $496.4 -5% Repligen Corp....
BioCentury | May 1, 2019
Financial News

May 1 Financial Quick Takes: Repligen, Translate Bio

...Repligen raises $175M follow-on Bioprocessing company Repligen Corp. (NASDAQ:RGEN) raised $175 million through the sale of 2.7...
...in a private placement through the sale of 5.6 million shares at $8.50. Brian Moy, Assistant Editor Repligen Corp. Translate...
BioCentury | Dec 14, 2018
Product R&D

Gene therapy’s make or buy choice

...their own production. Ransohoff is a chemical engineer who conducted GMP manufacturing at Xoma and Repligen Corp....
...NYSE:NVS; SIX:NOVN), Basel, Switzerland Orchard Therapeutics plc (NASDAQ:ORTX), London, U.K. RegenxBio Inc. (NASDAQ:RGNX), Rockville, Md. Repligen Corp....
BioCentury | Mar 7, 2018
Distillery Therapeutics

Cancer

...with vehicle. Next steps could include testing inhibitors of DCPS in additional models of AML. Repligen Corp....
BioCentury | Feb 12, 2018
Preclinical News

HDAC3 inhibition promotes peripheral remyelination

...BioMarin acquired the candidate from Repligen Corp. (NASDAQ:RGEN) in 2014. Chris Lieu BioMarin Pharmaceutical Inc. Cincinnati Children's Hospital Medical Center Repligen Corp. Histone...
BioCentury | Sep 26, 2017
Financial News

Repligen in precarious waters after GE launches in-house resin

...implications for the bioprocessing company. GE Healthcare is a unit of General Electric Co. (NYSE:GE). Repligen...
...Couillard said the long-term implications on Repligen's financial outlook are "hard to ignore," especially if Repligen's...
...of Repligen's 2016 revenues. Repligen reported revenues of $104.5 million in 2016. Elizabeth S. Eaton General Electric Co. Repligen Corp. MabSelect...
BioCentury | Jul 7, 2017
Finance

Generalists needed

...NASDAQ:BLUE) 6/27/17 $400.1 $4,699.8 $4,702.1 0% Neos Therapeutics Inc. (NASDAQ:NEOS) 6/27/17 $32.4 $184.7 $199.7 8% Repligen Corp....
BioCentury | Jul 7, 2017
Financial News

Repligen raises $120M follow-on

...On June 27, bioprocessing company Repligen Corp. (NASDAQ:RGEN) raised $120 million through the sale of 2.8 million...
...follow-on underwritten by JPMorgan, Stephens, Janney Montgomery Scott and Craig-Hallum Capital. Repligen Corp. (NASDAQ:RGEN), Waltham, Mass. Alicia Parker Repligen Corp....
BioCentury | May 23, 2016
Financial News

Repligen completes private placement of senior convertible notes

Repligen Corp. (NASDAQ:RGEN), Waltham, Mass. Business: Biomanufacturing, Supply/Service Date completed: 2016-05-19 Type: Private placement of senior convertible notes Raised: $100 million Shares outstanding prior: 33.6 million Underwriters: Jefferies; Janney Montgomery Scott; Craig-Hallum Capital Group Note:...
Items per page:
1 - 10 of 292
BioCentury | Jul 18, 2019
Financial News

July 17 Financial Quick Takes: Chipscreen's Shanghai listing advances; plus Avrobio, Repligen and Seer

...13%) to $8.76 on Wednesday. Repligen raises $370M via sales of stock, notes Bioprocessing company Repligen Corp....
...million shares at $87 in an upsized follow-on. The price is a 1.2% premium to Repligen’s...
...CMS, joined its board. Undisclosed other investors participated in the financing. Hongjiang Li, Staff Writer AVR-RD-01, avr-02 Avrobio Inc. Repligen Corp. Seer...
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...NASDAQ:VCYT) 5/2/19 $147.1 $1,112.1 $1,363.8 23% Magenta Therapeutics Inc. (NASDAQ:MGTA) 5/1/19 $64.8 $520.6 $496.4 -5% Repligen Corp....
BioCentury | May 1, 2019
Financial News

May 1 Financial Quick Takes: Repligen, Translate Bio

...Repligen raises $175M follow-on Bioprocessing company Repligen Corp. (NASDAQ:RGEN) raised $175 million through the sale of 2.7...
...in a private placement through the sale of 5.6 million shares at $8.50. Brian Moy, Assistant Editor Repligen Corp. Translate...
BioCentury | Dec 14, 2018
Product R&D

Gene therapy’s make or buy choice

...their own production. Ransohoff is a chemical engineer who conducted GMP manufacturing at Xoma and Repligen Corp....
...NYSE:NVS; SIX:NOVN), Basel, Switzerland Orchard Therapeutics plc (NASDAQ:ORTX), London, U.K. RegenxBio Inc. (NASDAQ:RGNX), Rockville, Md. Repligen Corp....
BioCentury | Mar 7, 2018
Distillery Therapeutics

Cancer

...with vehicle. Next steps could include testing inhibitors of DCPS in additional models of AML. Repligen Corp....
BioCentury | Feb 12, 2018
Preclinical News

HDAC3 inhibition promotes peripheral remyelination

...BioMarin acquired the candidate from Repligen Corp. (NASDAQ:RGEN) in 2014. Chris Lieu BioMarin Pharmaceutical Inc. Cincinnati Children's Hospital Medical Center Repligen Corp. Histone...
BioCentury | Sep 26, 2017
Financial News

Repligen in precarious waters after GE launches in-house resin

...implications for the bioprocessing company. GE Healthcare is a unit of General Electric Co. (NYSE:GE). Repligen...
...Couillard said the long-term implications on Repligen's financial outlook are "hard to ignore," especially if Repligen's...
...of Repligen's 2016 revenues. Repligen reported revenues of $104.5 million in 2016. Elizabeth S. Eaton General Electric Co. Repligen Corp. MabSelect...
BioCentury | Jul 7, 2017
Finance

Generalists needed

...NASDAQ:BLUE) 6/27/17 $400.1 $4,699.8 $4,702.1 0% Neos Therapeutics Inc. (NASDAQ:NEOS) 6/27/17 $32.4 $184.7 $199.7 8% Repligen Corp....
BioCentury | Jul 7, 2017
Financial News

Repligen raises $120M follow-on

...On June 27, bioprocessing company Repligen Corp. (NASDAQ:RGEN) raised $120 million through the sale of 2.8 million...
...follow-on underwritten by JPMorgan, Stephens, Janney Montgomery Scott and Craig-Hallum Capital. Repligen Corp. (NASDAQ:RGEN), Waltham, Mass. Alicia Parker Repligen Corp....
BioCentury | May 23, 2016
Financial News

Repligen completes private placement of senior convertible notes

Repligen Corp. (NASDAQ:RGEN), Waltham, Mass. Business: Biomanufacturing, Supply/Service Date completed: 2016-05-19 Type: Private placement of senior convertible notes Raised: $100 million Shares outstanding prior: 33.6 million Underwriters: Jefferies; Janney Montgomery Scott; Craig-Hallum Capital Group Note:...
Items per page:
1 - 10 of 292